Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Nita A. Limdi"'
Autor:
Alana C. Jones, Amit Patki, Vinodh Srinivasasainagendra, Bertha A. Hidalgo, Hemant K. Tiwari, Nita A. Limdi, Nicole D. Armstrong, Ninad S. Chaudhary, Bré Minniefield, Devin Absher, Donna K. Arnett, Leslie A. Lange, Ethan M. Lange, Bessie A. Young, Clarissa J. Diamantidis, Stephen S. Rich, Josyf C. Mychaleckyj, Jerome I. Rotter, Kent D. Taylor, Holly J. Kramer, Russell P. Tracy, Peter Durda, Silva Kasela, Tuuli Lappalinen, Yongmei Liu, W. Craig Johnson, David J. Van Den Berg, Nora Franceschini, Simin Liu, Charles P. Mouton, Parveen Bhatti, Steve Horvath, Eric A. Whitsel, Marguerite R. Irvin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Chronic kidney disease (CKD) impacts about 1 in 7 adults in the United States, but African Americans (AAs) carry a disproportionately higher burden of disease. Epigenetic modifications, such as DNA methylation at cytosine-phosphate-guanine (
Externí odkaz:
https://doaj.org/article/12deb3d0ae334de99921176e9c1f291a
Autor:
Nicole D. Armstrong, Amit Patki, Vinodh Srinivasasainagendra, Tian Ge, Leslie A. Lange, Leah Kottyan, Bahram Namjou, Amy S. Shah, Laura J. Rasmussen-Torvik, Gail P. Jarvik, James B. Meigs, Elizabeth W. Karlson, Nita A. Limdi, Marguerite R. Irvin, Hemant K. Tiwari
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Type 2 diabetes (T2D) is caused by both genetic and environmental factors and is associated with an increased risk of cardiorenal complications and mortality. Though disproportionately affected by the condition, African Americans (AA) are la
Externí odkaz:
https://doaj.org/article/d5034e28612d4f249c9d2e4426faf605
Autor:
Justin D. Anderson, Brittney H. Davis, Gracie Giang, April Jones, Cameron R. Lee, Kennedy Parker, Heather Searcy, Kim Benner, Nita A. Limdi, Jennifer S. Guimbellot
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 662-672 (2023)
Abstract Although major advancements have been made in the therapeutics for people with cystic fibrosis (PwCF), many still require the use of multiple medications to manage acute exacerbations of disease and maintain health. Iterative trial and error
Externí odkaz:
https://doaj.org/article/b734a72b88724adebf45a12faeb66cf3
Autor:
Tian Ge, Marguerite R. Irvin, Amit Patki, Vinodh Srinivasasainagendra, Yen-Feng Lin, Hemant K. Tiwari, Nicole D. Armstrong, Barbara Benoit, Chia-Yen Chen, Karmel W. Choi, James J. Cimino, Brittney H. Davis, Ozan Dikilitas, Bethany Etheridge, Yen-Chen Anne Feng, Vivian Gainer, Hailiang Huang, Gail P. Jarvik, Christopher Kachulis, Eimear E. Kenny, Atlas Khan, Krzysztof Kiryluk, Leah Kottyan, Iftikhar J. Kullo, Christoph Lange, Niall Lennon, Aaron Leong, Edyta Malolepsza, Ayme D. Miles, Shawn Murphy, Bahram Namjou, Renuka Narayan, Mark J. O’Connor, Jennifer A. Pacheco, Emma Perez, Laura J. Rasmussen-Torvik, Elisabeth A. Rosenthal, Daniel Schaid, Maria Stamou, Miriam S. Udler, Wei-Qi Wei, Scott T. Weiss, Maggie C. Y. Ng, Jordan W. Smoller, Matthew S. Lebo, James B. Meigs, Nita A. Limdi, Elizabeth W. Karlson
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-16 (2022)
Abstract Background Type 2 diabetes (T2D) is a worldwide scourge caused by both genetic and environmental risk factors that disproportionately afflicts communities of color. Leveraging existing large-scale genome-wide association studies (GWAS), poly
Externí odkaz:
https://doaj.org/article/e049f828882147afa27dd2a692f0bc18
Autor:
Ramzi G. Salloum, Jeffrey R. Bishop, Amanda L. Elchynski, D. Max Smith, Elizabeth Rowe, Kathryn V. Blake, Nita A. Limdi, Christina L. Aquilante, Jill Bates, Amber L. Beitelshees, Amber Cipriani, Benjamin Q. Duong, Philip E. Empey, Christine M. Formea, J. Kevin Hicks, Pawel Mroz, David Oslin, Amy L. Pasternak, Natasha Petry, Laura B. Ramsey, Allyson Schlichte, Sandra M. Swain, Kristen M. Ward, Kristin Wiisanen, Todd C. Skaar, Sara L. Van Driest, Larisa H. Cavallari, Sony Tuteja
Publikováno v:
Implementation Science Communications, Vol 3, Iss 1, Pp 1-9 (2022)
Abstract Background Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for dete
Externí odkaz:
https://doaj.org/article/622e160da30149b7bb83516b31e629d0
Autor:
Sony Tuteja, Ramzi G. Salloum, Amanda L. Elchynski, D. Max Smith, Elizabeth Rowe, Kathryn V. Blake, Nita A. Limdi, Christina L. Aquilante, Jill Bates, Amber L. Beitelshees, Amber Cipriani, Benjamin Q. Duong, Philip E. Empey, Christine M. Formea, J. Kevin Hicks, Pawel Mroz, David Oslin, Amy L. Pasternak, Natasha Petry, Laura B. Ramsey, Allyson Schlichte, Sandra M. Swain, Kristen M. Ward, Kristin Wiisanen, Todd C. Skaar, Sara L. Van Driest, Larisa H. Cavallari, Jeffrey R. Bishop, for the IGNITE Pharmacogenetics Working Group
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 371-383 (2022)
Abstract There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented o
Externí odkaz:
https://doaj.org/article/8db7d4a68b104a13ba4ac33d91a1855f
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2327-2338 (2021)
Abstract The evolution of evidence and availability of Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines have enabled assessment of pharmacogenetic (PGx) actionability and clinical implementation. However, population‐level action
Externí odkaz:
https://doaj.org/article/d2f206528b0f46e5aa0f3e0e2001aa3f
Autor:
Alessandra M. Campos-Staffico, Michael P. Dorsch, Geoffrey D. Barnes, Hao-Jie Zhu, Nita A. Limdi, Jasmine A. Luzum
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) are the first-line guideline-recommended therapy since they are a
Externí odkaz:
https://doaj.org/article/af9cafd7d4eb474ba36521f3cc5f0100
Autor:
Ninad S. Chaudhary, Nicole D. Armstrong, Bertha A. Hidalgo, Orlando M. Gutiérrez, Jacklyn N. Hellwege, Nita A. Limdi, Richard J. Reynolds, Suzanne E. Judd, Girish N. Nadkarni, Leslie Lange, Cheryl A. Winkler, Jeffrey B. Kopp, Donna K. Arnett, Hemant K. Tiwari, Marguerite R. Irvin
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundSome but not all African-Americans (AA) who carry APOL1 nephropathy risk variants (APOL1) develop kidney failure (end-stage kidney disease, ESKD). To identify genetic modifiers, we assessed gene–gene interactions in a large prospective co
Externí odkaz:
https://doaj.org/article/ea48565d903540c6ad32bf9b1b933bd3
Autor:
Alessandra M. Campos-Staffico, Michael P. Dorsch, Geoffrey D. Barnes, Haojie Zhu, Nita A. Limdi, Jasmine A. Luzum
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 83-83 (2023)
OBJECTIVES/GOALS: Assess the association of PK-related single nucleotide variants (SNVs) with the risk of bleeding from DOACs in non-valvular AF patients. METHODS/STUDY POPULATION: A retrospective cohort study was carried out with 2,364 Caucasians wi
Externí odkaz:
https://doaj.org/article/4fd42b5c6e4b427ab6c2d8a7641b45bd